Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
www.Emergent.com is wrong web site.
What is symbol for Emergent ?
The only thing 14 employees can produce is HYPE. IMHO.
I am not claiming any thing.
I sold VXRT AT 16.30 as soon as I found out there were only 14 employees.
As I said HYPE !
OWS has not given any money to VXRT
Good luck
Why would "Operation Warp Speed Funding" give money to a company with only 14 employees ????
There must be better data out there.
AstraZeneca total number of employees in 2019 was 0, a 100% decline from 2018.
AstraZeneca total number of employees in 2018 was 64,400, a 5.4% increase from 2017.
AstraZeneca total number of employees in 2017 was 61,100, a 2.35% increase from 2016.
AstraZeneca total number of employees in 2016 was 59,700, a 2.93% decline from 2015.
This company has 12 employees.
Right now they can not make any thing !
May be pr0fit in future
May have entered phase 3 ?
Market Cap = 157.09B
PE Ratio = 93.90
SVA China may beat the USA with a vaccine
Studied the details using the internet .
The key fact is they have a phase 3 going on now.
Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial
This is only 3rd company in the world to go to phase 3
Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial
ONLY 3RD IN PHASE 3 TRIAL OF COVID 19 VACCINE
PE Ratio = 20.20
Revenue=$ 246.05M
Market Cap = .639 B
phase 3 testing
AZN
MRNA
SINOVAC
Chinese drugmaker Sinovac reported in June that its COVID-19 vaccine candidate CoronaVac produced neutralizing antibodies in over 90% of patients in a phase 1/2 clinical study. Results from a phase 1 study of AZD1222, the COVID-19 vaccine candidate being developed by AstraZeneca and the University of Oxford, are expected to be published on July 20 in The Lancet medical journal.
Motley Fool Returns
Stock Advisor S&P 500
473% 97%
Stock Advisor launched in February of 2002. Returns as of 07/19/2020.
Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return Motley Fools Stock Advisor has out performed the market by over 200% over the last 18 years
Stocks
MRNA
Moderna, Inc. Stock Quote
Moderna, Inc.
NASDAQ:MRNA
$94.85
up
$13.04
(15.94%)
PFE
Pfizer Inc. Stock Quote
Pfizer Inc.
NYSE:PFE
$36.25
up
$0.65
(1.83%)
AZN
AstraZeneca PLC Stock Quote
AstraZeneca PLC
NYSE:AZN
$61.10
up
$3.67
(6.39%)
NVAX
Novavax, Inc. Stock Quote
Novavax, Inc.
NASDAQ:NVAX
$140.49
up
$20.20
(16.79%)
BNTX
BioNTech SE Stock Quote
BioNTech SE
NASDAQ:BNTX
$85.25
up
$9.38
(12.36%)
Related Articles
3 Coronavirus Stocks That Could Make You a Fast Fortune
Should You Sell These 2 Coronavirus Stocks That Robinhood Investors Love?
The 1 Number Healthcare Investors Should Consider When a Company Releases Study Results
Which Biotech Company Has the Most Promising Coronavirus Vaccine?
Why Moderna Stock Soared to a New All-Time High Today
Why Is Moderna Already Making Coronavirus Vaccine Doses?
The company's preparing to ship a product that hasn't even begun late-stage testing.
Cory Renauer
Cory Renauer
(TMFang4apples)
Jul 16, 2020 at 1:38PM
Author Bio
Follow @@coryrenauer
The race to develop a coronavirus vaccine is moving forward rapidly, and some drugmakers have taken an unusual step to rapidly deploy their respective vaccines the moment the Food and Drug Administration gives the green light. Moderna (NASDAQ:MRNA) is the latest drugmaker to begin manufacturing millions of doses of its still-experimental vaccine, mRNA-1273, at risk.
During a recent conference call to discuss encouraging phase 1 trial results for mRNA-1273, CEO Stephane Bancel sketched out a plan to produce enough doses to vaccinate everybody in the U.S. In fact, the company thinks it can produce between 500 million and 1 billion doses annually. At the moment, Moderna and its manufacturing partners are producing doses of mRNA-1273 at three sites for the U.S. market.
Vials labeled as containing cronavirus vaccine and a stack of cash.
Image source: Getty Images.
During a phase 1 clinical trial, all 45 patients had antibodies in their bloodstream produced in response to mRNA-1273. But the immune system produces lots of different antibodies when it encounters anything foreign, so unfortunately it's hard to draw any meaningful conclusions from the results.
Volunteers vaccinated with mRNA-1273 produced high levels of some antibodies also seen in patients that have recovered from COVID-19. But we still have no idea whether or not high concentrations of those antibodies will effectively prevent SARS-CoV-2 from spreading.
By the end of July, Moderna plans to begin a 30,000-patient phase 3 study with mRNA-1273 that was previously scheduled to begin on July 9. The pivotal study was delayed because the company was late to submit final protocol changes to the FDA. The delay puts mRNA-1273 behind AZD1222 from AstraZeneca (NYSE:AZN), another coronavirus vaccine candidate that began a 5,000-patient phase 3 trial in Brazil at the end of June.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Motley Fool Returns
Stock Advisor S&P 500
473% 97%
Stock Advisor launched in February of 2002. Returns as of 07/19/2020.
Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return Motley Fools Stock Advisor has out performed the market by over 200% over the last 18 years
Stocks
MRNA
Moderna, Inc. Stock Quote
Moderna, Inc.
NASDAQ:MRNA
$94.85
up
$13.04
(15.94%)
AZN
AstraZeneca PLC Stock Quote
AstraZeneca PLC
NYSE:AZN
$61.10
up
$3.67
(6.39%)
Read More
Here Are All the COVID-19 Vaccines Currently in Clinical Testing
3 Coronavirus Stocks That Could Make You a Fast Fortune
Should You Sell These 2 Coronavirus Stocks That Robinhood Investors Love?
The 1 Number Healthcare Investors Should Consider When a Company Releases Study Results
Which Biotech Company Has the Most Promising Coronavirus Vaccine?
AUG AND SEP SEASONALITY BAD MONTHS
JULY 17 ART HILL UP = 4 D0WN =5
Still bearish
Employee Count 8
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to milciclib, the Company is also developing foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody known to the company in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
May be worth following
PE Ratio = -0.36
Float =33.28M
Market Cap =350 M